Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2011 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: The Dodgy Ticker who wrote (39)	12/31/2010 5:26:11 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 400

>…maybe we should say pharmas are now OK in the contest.< When were they not Ok? BMY was one of my 2010 picks.

To: The Dodgy Ticker who wrote (39)	12/31/2010 7:58:53 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 400

You've entered this contest for ages, winning recently. I see/feel your point, and distinctions of this type really bugged me for ages. "Biotech" was good, and "pharma" was the enemy that we all needed. I would argue that the lines HAVE blurred, and that yahoo ain't the authority. But I don't feel strongly, and I'm glad to see the discussion. At one time, this contest had no alternative but to be all about small caps. ALL bios were small caps. ;-) (Contest was going for a few years before I ever entered a portfolio. In the old days, we had to keep guys like Mike Mc. from entering companies that had share prices of $0.0000004.) Happy New Year, Bob! Rick

To: The Dodgy Ticker who wrote (39)	1/1/2011 2:58:59 AM
From: technetium	Respond to of 400

Yahoo gives "Biotech" under industry for AMGN and GILD, but "Drug manufacturers--major" for ABT and MRK As far as I can tell the distinction between "biotech" and "pharma" is whether they trade on the NASDAQ (i.e., four letter tickers) versus the NYSE (three letter tickers.) I'll ignore the AMEX, as they're good for ETFs, but not where you want to see a biotech traded. This contest favors those who knock the ball out of the park and score with bases loaded. The flip side is striking out and retiring the side, rather than advance on singles. The former favors small cap biotechs over large cap, especially when companies like AMGN do so well for so long you don't expect a huge spike in stock price. Many biotechs are expensive, so steady growth earners with sedate positive returns look good in 2011, so pick now and sit tight until next year.